论文部分内容阅读
规范化的早产儿呼吸窘迫综合征 (ＲＤＳ)的治疗是应用肺表面活性物质 ,多中心临床试验研究表明肺表面活性物质能够减轻ＲＤＳ并减少死亡 ,但支气管肺发育不全 (ＢＰＤ)并没有相应同步地减少 ,可能是因为极不成熟儿 (具有发生ＢＰＤ高危因素 )因使用肺表面活性物质而存活。许多?
Standardized treatment of respiratory distress syndrome (RDS) in preterm infants is the use of pulmonary surfactant, and multicenter clinical trials have shown that pulmonary surfactant can reduce RDS and reduce mortality, but bronchopulmonary hypoplasia (BPD) is not synchronized This may be due to the survival of very immature infants (who are at high risk for developing BPD) due to the use of pulmonary surfactant. a lot of?